Enago in collaboration with AntiCancer, Inc.—the world’s leading preclinical cancer contract research organization—conducted an advanced session on cancer research studies. Dr. Robert M. Hoffman (President, Chairman of Board and CEO, AntiCancer, Inc.), a veteran scientist who discovered the methionine addiction of cancer (Hoffman Effect), described the mechanism of the methionine addiction and how this fundamental hallmark of all cancers can be targeted therapeutically.
With 55+ years of significant contribution to science, Dr. Hoffman has done pioneering research studies to provide treatment for cancer. In this session, Dr. Hoffman focussed on discussing the following key topics related to methionine addiction:
- What is the Hoffman effect?
- Everything about methionine addiction and its importance in cancer
- Role of methylation and transmethylation reactions
- Which is the most powerful form of PET imaging in cancer?
- Cancer treatment using methionine restriction
About the Speaker
Dr. Robert M. Hoffman
Summarising his 55 years of research in cancer, Dr. Hoffman discovered methionine addiction of cancer in 1976 and has shown that methionine addiction is the fundamental and general hallmark of cancer. Methionine addiction of cancer is named the Hoffman Effect after Dr. Hoffman. Together with his team, Dr. Hoffman is developing methioninase as a general cancer therapeutic that targets methionine addiction. Further, Dr. Hoffman is also a world leader in mouse models of cancer, three dimensional tumor culture, bacterial therapy of cancer, in vivo imaging of cancer, adult stem cells. and precision medicine for cancer.